QQQ   422.83 (-0.14%)
AAPL   166.82 (-0.13%)
MSFT   404.90 (+0.16%)
META   506.50 (+0.94%)
GOOGL   155.40 (-0.39%)
AMZN   178.78 (-0.25%)
TSLA   149.20 (-0.49%)
NVDA   846.50 (-0.02%)
AMD   154.33 (-0.48%)
NIO   3.87 (-3.25%)
BABA   68.49 (-0.57%)
T   16.25 (-0.49%)
F   12.05 (-0.08%)
MU   109.77 (-1.93%)
GE   152.90 (-0.03%)
CGC   7.60 (-2.94%)
DIS   111.77 (-0.59%)
AMC   2.89 (-1.03%)
PFE   25.41 (+0.08%)
PYPL   62.02 (-0.13%)
XOM   118.75 (+0.19%)
QQQ   422.83 (-0.14%)
AAPL   166.82 (-0.13%)
MSFT   404.90 (+0.16%)
META   506.50 (+0.94%)
GOOGL   155.40 (-0.39%)
AMZN   178.78 (-0.25%)
TSLA   149.20 (-0.49%)
NVDA   846.50 (-0.02%)
AMD   154.33 (-0.48%)
NIO   3.87 (-3.25%)
BABA   68.49 (-0.57%)
T   16.25 (-0.49%)
F   12.05 (-0.08%)
MU   109.77 (-1.93%)
GE   152.90 (-0.03%)
CGC   7.60 (-2.94%)
DIS   111.77 (-0.59%)
AMC   2.89 (-1.03%)
PFE   25.41 (+0.08%)
PYPL   62.02 (-0.13%)
XOM   118.75 (+0.19%)
QQQ   422.83 (-0.14%)
AAPL   166.82 (-0.13%)
MSFT   404.90 (+0.16%)
META   506.50 (+0.94%)
GOOGL   155.40 (-0.39%)
AMZN   178.78 (-0.25%)
TSLA   149.20 (-0.49%)
NVDA   846.50 (-0.02%)
AMD   154.33 (-0.48%)
NIO   3.87 (-3.25%)
BABA   68.49 (-0.57%)
T   16.25 (-0.49%)
F   12.05 (-0.08%)
MU   109.77 (-1.93%)
GE   152.90 (-0.03%)
CGC   7.60 (-2.94%)
DIS   111.77 (-0.59%)
AMC   2.89 (-1.03%)
PFE   25.41 (+0.08%)
PYPL   62.02 (-0.13%)
XOM   118.75 (+0.19%)
QQQ   422.83 (-0.14%)
AAPL   166.82 (-0.13%)
MSFT   404.90 (+0.16%)
META   506.50 (+0.94%)
GOOGL   155.40 (-0.39%)
AMZN   178.78 (-0.25%)
TSLA   149.20 (-0.49%)
NVDA   846.50 (-0.02%)
AMD   154.33 (-0.48%)
NIO   3.87 (-3.25%)
BABA   68.49 (-0.57%)
T   16.25 (-0.49%)
F   12.05 (-0.08%)
MU   109.77 (-1.93%)
GE   152.90 (-0.03%)
CGC   7.60 (-2.94%)
DIS   111.77 (-0.59%)
AMC   2.89 (-1.03%)
PFE   25.41 (+0.08%)
PYPL   62.02 (-0.13%)
XOM   118.75 (+0.19%)
Free Trial
NASDAQ:VTYX

Ventyx Biosciences (VTYX) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)
Free VTYX Stock Alerts
$4.14
-0.21 (-4.83%)
(As of 08:33 AM ET)
Compare
Today's Range
$4.14
▼
$4.14
50-Day Range
$2.29
▼
$10.13
52-Week Range
$1.87
▼
$40.58
Volume
1,435 shs
Average Volume
3.78 million shs
Market Capitalization
$291.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.75
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media

Ventyx Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
400.0% Upside
$21.75 Price Target
Short Interest
Healthy
19.58% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.05mentions of Ventyx Biosciences in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$39,787 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.55) to ($2.47) Per Share

Overall MarketRank™

New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.65 out of 5 stars

Medical Sector

420th out of 918 stocks

Pharmaceutical Preparations Industry

191st out of 429 stocks

See Top Rated MarketRank™ Stocks Here
VTYX stock logo

About Ventyx Biosciences Stock (NASDAQ:VTYX)

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

VTYX Stock Price History

VTYX Stock News Headlines

April 4, 2024 | insidertrades.com
Raju Mohan Sells 4,312 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) Stock
April 19, 2024 | markets.businessinsider.com
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ventyx Biosciences
April 19, 2024 | Altimetry (Ad)
I’m officially sounding the alarm.
AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.
April 19, 2024 | prnewswire.com
Ventyx Biosciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 30, 2024 to Discuss Your Rights - VTYX
April 18, 2024 | msn.com
Big Pharma Targets Weight-Loss Drug Firms for Buyouts: Here are 4 Potential Candidates
April 17, 2024 | markets.businessinsider.com
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ventyx Biosciences
April 17, 2024 | markets.businessinsider.com
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm
April 16, 2024 | prnewswire.com
VTYX Investors Have Opportunity to Lead Ventyx Biosciences, Inc. Securities Fraud Lawsuit
April 19, 2024 | Altimetry (Ad)
I’m officially sounding the alarm.
AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.
April 16, 2024 | prnewswire.com
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 30, 2024 in Ventyx Biosciences, Inc. Lawsuit - VTYX
April 15, 2024 | markets.businessinsider.com
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm
April 15, 2024 | prnewswire.com
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 30, 2024 in Ventyx Biosciences, Inc. Lawsuit - VTYX
April 14, 2024 | prnewswire.com
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTYX
April 13, 2024 | prnewswire.com
INVESTOR INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ventyx Biosciences
April 12, 2024 | prnewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - VTYX
April 12, 2024 | prnewswire.com
The Gross Law Firm Reminds Ventyx Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYX
April 11, 2024 | markets.businessinsider.com
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm
April 11, 2024 | americanbankingnews.com
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Average Recommendation of "Moderate Buy" from Analysts
April 10, 2024 | markets.businessinsider.com
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm
April 10, 2024 | msn.com
Ventyx Biosciences drops 3%, stockholders to sell ~11.17M shares
April 10, 2024 | prnewswire.com
Levi & Korsinsky Reminds Ventyx Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYX
April 9, 2024 | prnewswire.com
VTYX Investors Have Opportunity to Lead Ventyx Biosciences, Inc. Securities Fraud Lawsuit
April 9, 2024 | prnewswire.com
Investors in Ventyx Biosciences, Inc. Should Contact The Gross Law Firm Before April 30, 2024 to Discuss Your Rights - VTYX
April 8, 2024 | markets.businessinsider.com
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ventyx
April 8, 2024 | markets.businessinsider.com
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm
April 8, 2024 | prnewswire.com
April 30, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against VTYX
April 7, 2024 | prnewswire.com
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTYX
See More Headlines
Receive VTYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ventyx Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
4/19/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VTYX
CUSIP
N/A
CIK
1851194
Web
www.ventyxbio.com
Phone
760-593-4832
Fax
N/A
Employees
79
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.75
High Stock Price Target
$62.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+400.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.30)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-192,960,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-62.58%
Return on Assets
-57.42%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
11.87
Quick Ratio
11.87

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.13 per share
Price / Book
1.05

Miscellaneous

Outstanding Shares
70,500,000
Free Float
53,304,000
Market Cap
$306.68 million
Optionable
Optionable
Beta
0.27
Beginners Guide To Retirement Stocks Cover
Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

VTYX Stock Analysis - Frequently Asked Questions

Should I buy or sell Ventyx Biosciences stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ventyx Biosciences in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VTYX shares.
View VTYX analyst ratings or view top-rated stocks.

What is Ventyx Biosciences' stock price target for 2024?

9 equities research analysts have issued 1 year price objectives for Ventyx Biosciences' shares. Their VTYX share price targets range from $5.00 to $62.00. On average, they predict the company's stock price to reach $21.75 in the next twelve months. This suggests a possible upside of 400.0% from the stock's current price.
View analysts price targets for VTYX or view top-rated stocks among Wall Street analysts.

How have VTYX shares performed in 2024?

Ventyx Biosciences' stock was trading at $2.47 on January 1st, 2024. Since then, VTYX stock has increased by 76.1% and is now trading at $4.35.
View the best growth stocks for 2024 here.

When is Ventyx Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our VTYX earnings forecast.

How were Ventyx Biosciences' earnings last quarter?

Ventyx Biosciences, Inc. (NASDAQ:VTYX) announced its quarterly earnings results on Tuesday, February, 27th. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.08. During the same period in the prior year, the firm posted ($0.62) earnings per share.

What ETFs hold Ventyx Biosciences' stock?

ETFs with the largest weight of Ventyx Biosciences (NASDAQ:VTYX) stock in their portfolio include Alger Mid Cap 40 ETF (FRTY).iShares U.S. Pharmaceuticals ETF (IHE).

When did Ventyx Biosciences IPO?

Ventyx Biosciences (VTYX) raised $152 million in an initial public offering on Thursday, October 21st 2021. The company issued 9,472,656 shares at $15.00-$17.00 per share.

How do I buy shares of Ventyx Biosciences?

Shares of VTYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VTYX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
Your Money is Not Safe
American Alternative
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research